Guzzo Isabella, Morolli Federica, Camassei Francesca Diomedi, Piazza Antonina, Poggi Elvira, Dello Strologo Luca
Nephrology Unit, Department of Pediatrics, Institute for Scientific Research, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy.
Pathology Unit, Department of Laboratories, Institute for Scientific Research, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165, Rome, Italy.
Pediatr Nephrol. 2017 Jan;32(1):185-188. doi: 10.1007/s00467-016-3500-8. Epub 2016 Oct 17.
Several cases of severe antibody-mediated rejection (AMR) secondary to antibodies against the angiotensin II type 1 receptor (AT1R-Ab) have been described with variable outcome.
CASE-DIAGNOSIS/TREATMENT: We report the case of a 13-year-old boy whose first kidney transplant failed due to steroid-resistant acute cellular rejection, with the subsequent development of sensitization. He received a second kidney transplant which was complicated by early humoral rejection, with weakly positive staining for the complement degradation product C4d. Test results were negative for donor-specific antibodies against human leukocyte antigens (HLA-DSA) and MHC class I-related chain A (MICA) but positive for AT1R-Ab. Retrospective testing of the sera collected during the first kidney transplant was also positive for AT1R-Ab. We therefore hypothesized that the failure of the first transplant was secondary to the same cause. Losartan was immediately introduced into the therapeutic regimen, and the patient showed an excellent clinical and histological recovery.
Testing for AT1R-Ab in any hypertensive patient with acute rejection who tests negative or weakly positive for C4d and negative for HLA-DSA and who is refractory to therapy is highly advisable. Pre-transplant AT1R-Ab may be indicative of the outcome in patients whose first transplant failed. Prompt initiation of treatment with losartan-immediately after transplantation in patients with pre-existing AT1R-Ab-should be encouraged.
已有数例因抗血管紧张素II 1型受体抗体(AT1R-Ab)继发的严重抗体介导性排斥反应(AMR)的病例报道,其结局各异。
病例诊断/治疗:我们报告了一名13岁男孩的病例,其首次肾移植因类固醇抵抗性急性细胞排斥反应而失败,并随后出现致敏。他接受了第二次肾移植,术后并发早期体液排斥反应,补体降解产物C4d染色弱阳性。针对人类白细胞抗原(HLA-DSA)和MHC I类相关链A(MICA)的供体特异性抗体检测结果为阴性,但AT1R-Ab检测结果为阳性。对首次肾移植期间采集的血清进行回顾性检测,AT1R-Ab也呈阳性。因此,我们推测首次移植失败是由同一原因所致。立即将氯沙坦纳入治疗方案,患者临床和组织学恢复良好。
对于任何患有急性排斥反应、C4d检测呈阴性或弱阳性、HLA-DSA检测呈阴性且治疗无效的高血压患者,检测AT1R-Ab是非常必要的。移植前的AT1R-Ab可能预示首次移植失败患者的结局。对于术前已存在AT1R-Ab的患者,应鼓励在移植后立即迅速开始使用氯沙坦治疗。